By Samuel Fitch When we think of the word reset, we often picture restarting a computer or a phone. Most problems on a device can be fixed with a simple restart. But when it comes to us—our physical, human selves—we don’t … Continue reading → Source: blog.mymsaa.org
Category: Multiple Sclerosis Research
Anti-CD20 are not all equal
Tweet Know one you know them all? Are the CD20-depleting antibodies all the same?. You would think so, as they all deplete CD20 positive B cells but this study says that rituximab causes more infections than ocrelizumab. The weird thing is other people are saying that ocrelizumab is better than rituximab based on MSbase. Roos…
Under starters orders and we are off
Tweet It was demanded that I post as many EAE and Mouse posts as possible from ECTRIMS2025… so happy to oblige. The first post from ECTRIMS2025 is about anti-CD40 ligand this blocks T cells interacting with B cells to deliver their activating signal. However a question I have posed to the students is what does…
Under starters orders and we are off
Tweet It was demanded that I post as many EAE and Mouse posts as possible from ECTRIMS2025… so happy to oblige. The first post from ECTRIMS2025 is about anti-CD40 ligand this blocks T cells interacting with B cells to deliver their activating signal. However a question I have posed to the students is what does…
ECTRIMS2025
Tweet Next up ….Especially for the Requester..Re-inventing a mouse model of EAE…..here we take a mouse that is is essentially empty of mouse T and B cells so we can fill it full of human cells and here they make MOG-reactive CAR-T cells and it makes lesions abit like the Transgenic MOG T cell receptor…
Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new study […] The post Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
New blood test for MS receives major commercialization funding
Octave Bioscience has raised $35.6 million in funding to continue marketing its multiple sclerosis (MS) disease activity test and accelerate the development of a similar tool for Parkinson’s disease. The […] The post New blood test for MS receives major commercialization funding appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Safety of Rituximab versus Ocrelizumab
Tweet A recent US multi-center study involving over 1,400 patients with multiple sclerosis (MS) has found that those treated with rituximab experienced significantly higher rates of hospitalizations, infections, and hypogammaglobulinemia compared to patients on ocrelizumab. The study analyzed data from UCSF and a larger University of California–wide cohort over a four-year follow-up period. At UCSF,…
New partnership bringing MS biosimilar drug to MENA region
Three biosimilar drugs — approved versions of brand-name therapies that have no clinically meaningful differences compared with their reference products — including one for multiple sclerosis (MS), will soon be […] The post New partnership bringing MS biosimilar drug to MENA region appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
HSCT in the UK
Tweet This paper looks at the outcome of HSCT in the United Kingdom and I guess one question is what DMT can compare? NEDA is no relapse no progression and no MRI so how does the good news on no relapse, no progression and no MRI equate to about 55% having disease? Real-world effectiveness of…